Skip to content

Idenix Pharmaceuticals LLC v. Gilead Sciences Inc.

Petition for certiorari denied on January 19, 2021

Docket No. Op. Below Argument Opinion Vote Author Term
20-380 Fed. Cir. N/A N/A N/A N/A OT 2020

Issue: (1) Whether, as the U.S. Court of Appeals for the Federal Circuit has held, a genus claim is not enabled "as a matter of law" if it encompasses a large number of compounds " or whether, as the Supreme Court has recognized, enablement is a context-specific jury question; and (2) whether, as the Federal Circuit has held, 35 U.S.C. § 112(a) contains a separate "possession" requirement " or whether, as the statute provides, Section 112(a) sets forth a single substantive requirement of "a written description of the invention" sufficient "to enable any person skilled in the art " to make and use the same."

DateProceedings and Orders (key to color coding)
09/21/2020Petition for a writ of certiorari filed. (Response due October 26, 2020)
10/09/2020Waiver of right of respondent Gilead Sciences, Inc. to respond filed.
10/14/2020DISTRIBUTED for Conference of 10/30/2020.
10/16/2020Response Requested. (Due November 16, 2020)
10/30/2020Motion to extend the time to file a response from November 16, 2020 to December 16, 2020, submitted to The Clerk.
11/02/2020Motion to extend the time to file a response is granted and the time is extended to and including December 16, 2020.
11/16/2020Brief amicus curiae of GLAXOSMITHKLINE PLC. filed.
11/16/2020Brief amicus curiae of Intellectual Property Professors filed.
11/16/2020Brief amicus curiae of Amgen Inc. filed.
12/16/2020Brief of respondent Gilead Sciences, Inc. in opposition filed.
12/30/2020DISTRIBUTED for Conference of 1/15/2021.
12/30/2020Reply of petitioners Universita Degli Studi di Cagliari filed. (Distributed)
01/19/2021Petition DENIED.